Your session is about to expire
← Back to Search
OBI-3424 for T-Cell Acute Lymphoblastic Leukemia
Study Summary
This trial looks at how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back or does not respond to treatment. OBI-3424 may reduce the amount of leukemia in the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have chronic hepatitis B but my viral load is undetectable or I am on treatment.I can take care of myself but may not be able to do heavy physical work.I haven't had nelarabine therapy, and my doctor thinks other treatments won't work for me.I haven't had chemotherapy in the last 14 days, except for certain allowed medications.My kidney function, measured by creatinine clearance, is good.I do not have an uncontrolled infection.I am not pregnant or nursing and will use effective birth control during and up to 6 months after treatment.I have no signs of brain or spinal cord disease recently.I have HIV, am on effective treatment, and my last viral load was undetectable.I have relapsed or refractory T-cell acute lymphoblastic leukemia.My liver enzymes are within the acceptable range for the trial.I have not had a bone marrow transplant from a donor in the last 3 months.I am 18 years old or older.I have acute leukemia with at least 5% lymphoblasts in my blood or bone marrow.I haven't had severe reactions from a transplant in the last 3 months.I have hepatitis C but my viral load is undetectable or I am on treatment.My cancer did not respond or has returned after standard treatment.
- Group 1: Treatment (AKR1C3-activated prodrug OBI-3424)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this a new clinical trial?
"AKR1C3-activated Prodrug OBI-3424 has been under investigation since 2018, when the first study was completed with support from OBI Pharma, Inc. This initial study included 104 participants. After this Phase 1 & 2 trial showed success in 2018, there are now two active AKR1C3-activated Prodrug OBI-3424 trials taking place across 65 cities in a single country."
What other scientific research has been conducted with AKR1C3-activated Prodrug OBI-3424?
"OBI-3424, a prodrug that is activated by AKR1C3, was first studied in 2018 at the Rutgers Cancer Institute of New jersey. Out of the total 2 active clinical trials, many are being conducted in Henderson, Nevada."
In how many different medical clinics is this study being run today?
"Presently, this on-going clinical trial is being conducted out of GenesisCare USA - Henderson in Henderson, Nevada; 21st Century Oncology in Las Vegas, Minnesota; and GenesisCare USA - Las Vegas in Burnsville, Oregon. There are also 100 other sites running this study."
Has the FDA given the green light to use AKR1C3-activated Prodrug OBI-3424?
"OBI-3424, which is currently in Phase 2 trials, has some safety data to support its use but no efficacy data. Therefore, it was given a score of 2."
Are there any vacancies in this research for new participants?
"Indeed, the clinical trial is still ongoing and looking for 39 individuals at 100 different sites. The original posting was on 8/17/2020, with the most recent update being 11/9/2022 according to clinicaltrials.gov"
Share this study with friends
Copy Link
Messenger